Where does Icon Bioscience, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Icon Bioscience, Inc. ranks #29,040 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Icon Bioscience, Inc. hold?

Icon Bioscience, Inc. holds 9 US utility patents granted between 2016 and 2024, spanning 3 technology areas.

What is Icon Bioscience, Inc.'s Innovation Score?

Icon Bioscience, Inc. has an Innovation Score of 25.0 out of 100 (16th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Icon Bioscience, Inc. focus on?

Icon Bioscience, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Icon Bioscience, Inc.'s patent grant rate increasing or decreasing?

Icon Bioscience, Inc.'s recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Icon Bioscience, Inc.'s patents?

Icon Bioscience, Inc.'s patents average 12.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Icon Bioscience, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Icon Bioscience, Inc.

USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Icon ranks #29,040 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 3 technology areas.

#29,040
of 49,997 US assignees by volume: 16th percentile
by Innovation Score (25.0/100): 12.7
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29040 · US Corporation #29,040 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,040/49,997
PHOTO-FINISH Ibur
CPC-NARROW A61P · 3 areas
INNOV-THIN 25.0/100
CLAIMS-RICH 12.7 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ibur, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Icon’s 25.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (32%) Velocity 3.3 pts (13%) Breadth 6.1 pts (24%) Claim depth 7.6 pts (30%)

Qualcomm Incorporated · highest

85
Icon Bioscience · this assignee

25
3D Lighting… · lowest

7

What this shows Icon's Innovation Score is 25.0/100 (16th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Icon?

Each dot is one of Icon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Icon’s own 12.7 claims/patent is ABOVE the 11.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Icon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Icon's grants concentrate

Icon Bioscience, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 55.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (3 grants) versus a trough of 1 in 2016. By volume, Icon sits between Ibur, LLC and Idsc Holdings LLC.

Icon's three-year grant acceleration

Icon Bioscience, Inc. shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ibur

9
ICA Trinova

9
Icare Finland OY

9
ICG Licensing

9
Icos

9
ID Pharma

9
IDM Global

9
Idsc Holdings

9
Icon Bioscience ◀

9

What this shows Icon holds 9 patents at rank #29,024, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Icon

By rank, the assignees closest to #29,024 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Icon's primary technology class.

Icon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 16th percentile higher than 16% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Icon Bioscience, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	11.1%
2017	2	22.2%
2018	3	33.3%
2020	1	11.1%
2021	1	11.1%
2024	1	11.1%

Which technologies does Icon Bioscience, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Icon Bioscience, Inc.'s patent record in context - here's where to go next.

Icon Bioscience, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 55.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #29,040 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Icon Bioscience, Inc. against Ibur, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.